Lauren Leanza
Company: Eli Lilly & Co.
Job title: Vice President – US Market Access
Seminars:
Uncovering the Success of Dual Brand Strategy for Anti-Obesity Medications: Lessons Learnt from the GLP-1 Boom to Inform Future Strategies 3:30 pm
Defining what constitutes a dual brand strategy in the context of GLP-1 medications, considering separate brands for different indications, different dosages, and different marketing strategies Understanding the core motivations behind dual brand strategies for anti-obesity medications Analyzing the risks and benefits of dual brand strategy: why has this worked so well for Eli Lilly and…Read more
day: Conference Day One
Panel – Lessons Learnt from Obesity & Diabetes to Inform Market Access Strategies for Wider Cardiometabolic Indications 4:30 pm
Understanding common barriers to patient access and affordability for treatments in these areas to consider how cost-sharing arrangements can be effectively navigated Understanding how availability of existing treatments and the pipeline of new therapies differ across CVRM disease areas effects market access dynamics Uncovering best practices in market access that have been applied in one…Read more
day: Conference Day One
Panel Discussion: Examining the Potential for the Treat and Reduce Obesity Act to be Passed and the Implications of this Act on Market Access 12:00 pm
Analysing the potential impact of TROA on market access for AOMs and how expanded Medicare coverage could influence private payer behaviour Discussing the challenges of estimating the budgetary impact of the TROA, considering utilization rates, drug pricing and long-term cost savings associated with obesity reduction Understanding how the TROA could impact the pharmaceutical industry’s investment…Read more
day: Conference Day Two
Panel Discussion: Understanding Targeted Coverage for Obesity Drugs by Navigating Comorbidities, Payers & Pharma Acquisitions 3:30 pm
Discussion on the necessity of specific comorbidities such as, prediabetes, osteoarthritis, sleep apnea, heart failure, for obesity drug coverage Exploring the challenges payers face in adapting coverage policies for obesity drugs, including rapid policy changesRead more
day: Conference Day Two